Method of treatment using gh antagonist and somatostatin agonist

Disclosed is a method for attenuating the effects of growth hormone (GH) in a subject. The method comprises the administration of both a GH antagonist and a somatostatin agonist to said subject, simultaneously or separately, continuously or periodically. In one preferred embodiment of the method an extended release somatostatin agonist composition is administered monthly (such as ocreotide LAR/SANDOSTATIN LAR or Lanreoride autogel/SOMATULINE AUTOGEL) , and a conventional non-extended release GH antagonist composition is administered weekly (such as pegvisomant) .